High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial
Aroda VR, Jørgensen NB, Kumar B, et al.
Diabetes Care. 2025:dc242425.
Leggi
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Aroda VR, Jørgensen NB, Kumar B, et al.
Diabetes Care. 2025:dc242425.
Leggi
Knowler WC, Doherty L, Edelstein SL, et al.
Lancet Diabetes Endocrinol. Pub. online 28 Apr 2025.
Leggi
Lim CE, Pasternak B, Eliasson B, Ueda P
Diabetologia. Pub. online 2 May 2025.
Leggi
Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al.
Lancet Diabetes Endocrinol. Pub. online 30 Apr 2025.
Leggi
Wing S, Ray JG, Yau K, et al.
JAMA Intern Med. 2025:e250686.
Leggi
Panchal K, Lawson CA, Shabnam S, et al.
Diabetes Obes Metab. Pub. online 2 May 2025.
Leggi
Eeg-Olofsson K, Nathanson D, Spelman T, et al.
Diabetologia. Pub. online 24 Apr 2025.
Leggi
Chew BH, Ngiam KY
BMC Med. 2025;23(1):244
Leggi
Zhou J, Mychaleckyj JC, Onengut-Gumuscu S, et al.
Diabetologia. Pub. online 23 Apr 2025.
Leggi
Lee CMY, Gibson AA, Nassar N, Colagiuri S Diabetes Obes Metab. Pub. online 23 Apr 2025. Abstract e full text
Leggi